We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SynCo Bio Partners Signs Agreement with a Japanese Pharmaceutical Company
News

SynCo Bio Partners Signs Agreement with a Japanese Pharmaceutical Company

SynCo Bio Partners Signs Agreement with a Japanese Pharmaceutical Company
News

SynCo Bio Partners Signs Agreement with a Japanese Pharmaceutical Company

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SynCo Bio Partners Signs Agreement with a Japanese Pharmaceutical Company"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SynCo Bio Partners B.V. has announced that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company.

The undisclosed company’s product is a live biotherapeutic based anticancer drug. The project will first involve a consultancy phase, during which SynCo will assist the client with in-house process development.

The developed process will then be transferred to SynCo’s Amsterdam facility and scaled-up, prior to GMP manufacture for Phase I clinical trials, including fermentation, formulation and aseptic filling.

“We are extremely pleased to be working our first Japanese partner” commented SynCo’s CEO, Mr. Pierre Warffemius ”this is an exciting project for a leading Japanese business and I look forward to the successful completion of GMP manufacture, in the field of live biotherapeutics. This contract represents SynCo’s entry into the growing Japanese biotherapeutics market and is reflective of our continuing success in a very competitive GMP contract manufacturing market.”
Advertisement